3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Triple Negative Breast Neoplasms
5
Breast Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Transitional Cell
3
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Prostatic Neoplasms
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Lung Neoplasms
1
Lung Diseases
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Liver Failure
1
HRD Cancer
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Drug-Related Side Effects and Adverse Reactions
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Interventions
Specimen Handling
34
Carboplatin
32
pembrolizumab
28
Pemetrexed
27
Magnetic Resonance Spectroscopy
27
Cisplatin
22
Paclitaxel
15
Gemcitabine
13
durvalumab
12
Docetaxel
12
osimertinib
11
Nivolumab
11
atezolizumab
8
Immunoglobulin G
8
Disulfides
8
Taxes
7
Etoposide
7
130-nm albumin-bound paclitaxel
7
Radiotherapy
6
Radiosurgery
6
Radiation
6
Platinum
6
Cetuximab
6
Biopsy
6
X-Rays
5
1,2-diaminocyclohexaneplatinum II citrate
5
Ramucirumab
4
Observation
4
Irinotecan
4
Albumin-Bound Paclitaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
sacituzumab govitecan
×
30 days
×
Clear all
NCT05633667
2026-06-01
VELOCITY-Lung
Gilead Sciences
Phase 2
Active not recruiting
192 enrolled